Cargando…

Peroxisome Proliferator-Activated Receptors as a Therapeutic Target in Asthma

The complexity of the pathogenetic mechanisms of the development of chronic inflammation in asthma determines its heterogeneity and insufficient treatment effectiveness. Nuclear transcription factors, which include peroxisome proliferator-activated receptors, that is, PPARs, play an important role i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kytikova, Oxana Yu., Perelman, Juliy M., Novgorodtseva, Tatyana P., Denisenko, Yulia K., Kolosov, Viktor P., Antonyuk, Marina V., Gvozdenko, Tatyana A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201810/ https://www.ncbi.nlm.nih.gov/pubmed/32395125 http://dx.doi.org/10.1155/2020/8906968

Ejemplares similares

Molecular Targets of Fatty Acid Ethanolamides in Asthma
por: Kytikova, Oxana, et al.
Publicado: (2019)

Pro-Resolving Lipid Mediators in the Pathophysiology of Asthma
por: Kytikova, Oxana, et al.
Publicado: (2019)

Thermosensory Transient Receptor Potential Ion Channels and Asthma
por: Kytikova, Oxana Yu., et al.
Publicado: (2021)

Lipid-Induced Mechanisms of Metabolic Syndrome
por: Denisenko, Yulia K., et al.
Publicado: (2020)

1-O-alkyl-glycerols from Squid Berryteuthis magister Reduce Inflammation and Modify Fatty Acid and Plasmalogen Metabolism in Asthma Associated with Obesity
por: Denisenko, Yulia, et al.
Publicado: (2023)

Modification of the fatty acid composition of the erythrocyte membrane in patients with chronic respiratory diseases
por: Novgorodtseva, Tatyana P, et al.
Publicado: (2013)

The Mechanisms of the Regulation of Immune Response in Patients with Comorbidity of Chronic Obstructive Pulmonary Disease and Asthma
por: Kalinina, Elena P., et al.
Publicado: (2016)

Modification of fatty acids composition in erythrocytes lipids in arterial hypertension associated with dyslipidemia
por: Novgorodtseva, Tatyana P, et al.
Publicado: (2011)

Effect of the prolonged high-fat diet on the fatty acid metabolism in rat blood and liver
por: Zhukova, Natalia V, et al.
Publicado: (2014)

Impact of Atmospheric Microparticles on the Development of Oxidative Stress in Healthy City/Industrial Seaport Residents
por: Golokhvast, Kirill, et al.
Publicado: (2015)

Composition of fatty acids in plasma and erythrocytes and eicosanoids level in patients with metabolic syndrome
por: Novgorodtseva, Tatyana P, et al.
Publicado: (2011)

The degradation of airway tight junction protein under acidic conditions is probably mediated by transient receptor potential vanilloid 1 receptor
por: Xu, Rui, et al.
Publicado: (2013)

Effect of epithelium ATP release on cyclic pressure-induced airway mucus secretion
por: Tong, Jin, et al.
Publicado: (2014)

Effects of Scutellarin on MUC5AC Mucin Production Induced by Human Neutrophil Elastase or Interleukin 13 on Airway Epithelial Cells
por: Jiang, De-Peng, et al.
Publicado: (2011)

Triiodothyronine Represses MUC5AC Expression by Antagonizing Sp1 Binding to Its Promoter in Human Bronchial Epithelial HBE16 Cells
por: Wang, Xiaolong, et al.
Publicado: (2012)

Oxidative Stress Mediates the Disruption of Airway Epithelial Tight Junctions through a TRPM2-PLCγ1-PKCα Signaling Pathway
por: Xu, Rui, et al.
Publicado: (2013)

The Role of Toll-Like Receptors 2 and 4 in the Pathogenesis of Chronic Obstructive Pulmonary Disease
por: Sidletskaya, Karolina, et al.
Publicado: (2020)

The Degradation of Airway Epithelial Tight Junctions in Asthma Under High Airway Pressure Is Probably Mediated by Piezo-1
por: Zhou, Jia, et al.
Publicado: (2021)

Differences in the health-related quality of life in patients with asthma living in urban and rural areas in the Amur Region of Russian Federation
por: Perelman, Natalia L., et al.
Publicado: (2023)

Peroxisome proliferator-activated receptor α as a novel therapeutic target for schizophrenia
por: Wada, Yuina, et al.
Publicado: (2020)

Role of Toll-Like Receptor 2 in Regulation of T-Helper Immune Response in Chronic Obstructive Pulmonary Disease
por: Sidletskaya, Karolina A., et al.
Publicado: (2021)

Chondrosarcoma and Peroxisome Proliferator-Activated Receptor
por: Nishida, K., et al.
Publicado: (2008)

Peroxisome Proliferator-Activated Receptor Alpha Target Genes
por: Rakhshandehroo, Maryam, et al.
Publicado: (2010)

Nuclear Peroxisome Proliferator-Activated Receptors (PPARs) as Therapeutic Targets of Resveratrol for Autism Spectrum Disorder
por: Barone, Rita, et al.
Publicado: (2019)

Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases
por: Monsalve, Francisco A., et al.
Publicado: (2013)

Peroxisome Proliferator-Activated Receptors in Lung Cancer
por: Keshamouni, Venkateshwar G., et al.
Publicado: (2007)

Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism
por: Kersten, Sander
Publicado: (2008)

Peroxisome Proliferator-Activated Receptors in Diabetic Nephropathy
por: Kume, Shinji, et al.
Publicado: (2008)

Peroxisome Proliferator-Activated Receptors and Shock State
por: Esposito, Emanuela, et al.
Publicado: (2006)

Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer
por: Wagner, Nicole, et al.
Publicado: (2022)

The Role of Peroxisome Proliferator-Activated Receptors in Preeclampsia
por: Psilopatis, Iason, et al.
Publicado: (2023)

Osteoarthritis: Role of Peroxisome Proliferator-Activated Receptors
por: Sheng, Weibei, et al.
Publicado: (2023)

Peroxisome Proliferator-Activated Receptor δ: A Target with a Broad Therapeutic Potential for Drug Discovery
por: Gregoire, Francine M.
Publicado: (2008)

Is peroxisome proliferator-activated receptor gamma (PPARγ) a therapeutic target for the treatment of pulmonary hypertension?
por: Green, David E., et al.
Publicado: (2011)

Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental and clinical scenarios
por: Katoch, Swati, et al.
Publicado: (2022)

Astaxanthin as a Peroxisome Proliferator-Activated Receptor (PPAR) Modulator: Its Therapeutic Implications
por: Choi, Chang-Ik
Publicado: (2019)

A Role for Peroxisome Proliferator-Activated Receptors in the Immunopathology of Schistosomiasis?
por: Anthony, Barrie J., et al.
Publicado: (2012)

Enhanced Hepatocarcinogenicity Due to Agonists of Peroxisome Proliferator-Activated Receptors in Senescent Rats: Role of Peroxisome Proliferation, Cell Proliferation, and Apoptosis
por: Youssef, Jihan, et al.
Publicado: (2002)

Therapeutic Effects of a Novel Agonist of Peroxisome Proliferator-Activated Receptor Alpha for the Treatment of Diabetic Retinopathy
por: Deng, Guotao, et al.
Publicado: (2017)

Peroxisome Proliferator-Activated Receptor γ Is a Target for Halogenated Analogs of Bisphenol A
por: Riu, Anne, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_pj2aj18esae0ok8vt6k1d8hr6t